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Background: P21-activated protein kinase 1 (PAK1), a main downstream effector of small Rho GTPases, is
overexpressed in many malignancies. PAK1 overexpression is associated with poor prognosis in some tumor types,
including breast cancer, gastric cancer, and colorectal cancer. However, the expression and clinical relevance of
PAK1 expression in human pancreatic cancer remains unknown.
Methods: The present study investigated the clinical and prognostic significance of PAK1 expression in pancreatic
carcinoma. We examined and scored the expression of PAK1 by immunohistochemistry in 72 primary pancreatic
carcinoma samples and 20 liver metastatic samples. The relationships between PAK1 and clinicopathological
parameters and prognosis in primary and metastatic pancreatic cancer were analyzed.
Results: Among the total 92 cases, primary pancreatic cancer samples had a significantly higher rate (38/72, 52.8%) of
high PAK1 expression than liver metastatic samples (5/20, 25.0%) (P = 0.028). Among the 72 primary pancreatic cancer
patients, high PAK1 expression was associated with younger age (P = 0.038) and moderately or well differentiated
tumor (P = 0.007). Moreover, a positive relationship was found between high PAK1 expression and overall survival (OS)
(P < 0.005). Patients with high PAK1 expression had a better OS than those with low PAK1 expression. Univariate and
multivariate analysis by Cox regression including PAK1 and other prognostic pathological markers demonstrated high
PAK1 immunostaining as a prognostic factor for survival in pancreatic cancer patients (P < 0.005).
Conclusions: We report for the first time that PAK1 is a novel prognostic marker for pathologically confirmed human
pancreatic cancer. Reduced expression of PAK1 correlates with poor histological differentiation in pancreatic cancer.
Keywords: P21-activated protein kinase 1 (PAK1), Pancreatic cancer, Immunohistochemistry, PrognosisBackground
Pancreatic carcinoma (PC) is one of the most lethal hu-
man cancers. It is the fifth most common cancer and the
fourth leading cause of cancer-related mortality world-
wide, with a five-year survival rate less than 5% in all
stages [1,2]. Adenocarcinoma of the pancreatic ducts ac-
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unless otherwise stated.the median survival is only 3 to 6 months. The high
mortality rate of pancreatic cancer is largely attributed
to the lack of reliable methods for early detection and its
profound resistance to the existing conventional therap-
ies. To date, the only approach to cure this disease is
radical surgical resection, which improves the five-year
survival rate to approximately 20–25% [4]. However, due
to the absence of early symptoms and robust diagnostic
markers, only 10–20% of pancreatic cancer patients
present with potentially resectable disease. Most patients
have lost the chance of resection because of the very late
and difficult diagnosis. Furthermore, even after extensive
curative pancreatectomy, patients often have a high rate of
liver metastasis, resulting in a poor prognosis. In addition,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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rence without evidence of metastases, and 80% of patients
have local recurrence within two years after potentially
curative resections [5]. Therefore, there is an urgent need
to search for prognostic markers or therapeutic targets for
pancreatic cancer.
The Rho-family GTPases Rho, Rac and Cdc42 regulate
many intracellular processes through their interaction
with downstream effector proteins. The p21-associated
kinases (PAKs) were first discovered in a screen for pro-
teins that interact with the small G-proteins Rac1 and
Cdc42 in 1994 [6]. As a set of evolutionarily conserved
serine/threonine protein kinase, PAKs influence actin
polymerization by regulating cofilin and actin depoly-
merizing factor (ADF), which are actin binding proteins
that regulate cytoskeletal dynamics by severing and de-
polymerizing actin filaments [7,8]. Based on domain
structure, sequence homology and regulation, PAKs have
been classified into two groups: group I (PAK1 to PAK3)
and group II (PAK4 to PAK6) [9]. The regulatory mech-
anism of group I PAKs is considerably different from
group II family members [10]. In group I PAKs, the p21-
binding domain (PBD) in the N-terminal domain binds
Rac and Cdc42 to cause autophosphorylation of specific
sites in the N-terminal inhibitory domain, leading to a
conformational change that releases the autoinhibition
and activates the kinase activity [7]. Group I PAKs also
contain a proline-rich region that is associated with
binding to Nck, an adapter protein involved in the regu-
lation of actin cytoskeletal dynamics [11]. In contrast
with group I PAKs, group II PAKs have very little se-
quence N-terminal to the PBD. Without obvious autoinhi-
bitory regions as in group I PAKs, the group II PAKs are
constitutively active in cells. Crystal structures of phos-
phorylated and active catalytic domains of all three group
II PAKs reveal a monomeric conformation [12,13].
P21-activated protein kinase1 (PAK1), a member of
group I PAKs, is a main downstream effector of the small
Rho GTPases. PAK1 plays an essential role in cell signal-
ing and regulation of cellular functions including cell mo-
tility, cytoskeletal rearrangement, angiogenesis, mitosis
and survival. A previous study demonstrated that PAK1
kinase activity is required for the Ras-induced transform-
ation of fibroblast cells [14]. Many studies also suggest
that PAK1 may play a crucial role in cancer development.
In breast cancer, PAK1 expression and activity was in-
creased and correlated with a more malignant phenotype.
Experimental manipulation also revealed that a constitu-
tively active form of PAK1 could rapidly induce breast
cancer cell proliferation and aggressive cell phenotypes,
including anchorage-independent growth and mitotic
defects [15]. Subsequent investigations showed that the
expression and activity of PAK1 was upregulated in several
other human cancers. Overexpression of PAK1 wasobserved in gastric cancer and was associated with metas-
tasis and prognosis. Downregulation of PAK1 expression
reduced gastric cancer cell migration and invasion [16]. In
another study of gastric cancer, Liu et al. found that over-
expression of PAK1 was associated with progression, me-
tastasis and prognosis, likely by regulating the transcription
of cyclin B1 through nuclear factor-κB (NF- κB) [17]. Over-
expression of PAK1 was also found in colorectal cancer,
and PAK1 expression was significantly increased in aden-
omas, invasive carcinomas, and lymph node metastases
compared to normal colon [18]. Therefore, PAK1 has grad-
ually become a representative marker for cancers.
However, the role of PAK1 in pancreatic cancer re-
mains largely unknown. One study in a BALB/c mouse
model of human pancreatic adenocarcinoma xenografts
found overexpression of PAK1 in moderately to well dif-
ferentiated pancreatic cancer samples [19]. However,
there are no reports on the clinical significance of PAK1
in human pancreatic cancer. In this study, we investi-
gated PAK1 expression status and evaluated the prog-
nostic significance of PAK1 in human pancreatic cancer.
Methods
Patient information and tissue specimens
The study was approved by the Institutional Review Board
and Human Ethics Committee of Sun Yat-sen University
Cancer Center and the Affiliated Tumor Hospital of
Guangzhou Medical University. All individuals gave writ-
ten informed consent for participation in the study. The
present study included 72 paraffin-embedded primary
pancreatic cancer samples and 20 liver metastatic tissues
of pancreatic cancer that were recruited from the Sun
Yat-sen University Cancer Center and the Affiliated Tumor
Hospital of Guangzhou Medical University (Guangzhou,
China) between May 2005 and December 2012. Among
the total of 92 cases, 72 patients underwent surgical resec-
tion of pancreatic tumor, 9 patients underwent resection
of liver metastatic tumor and 11 patients had liver tissue
biopsy. Histomorphology of all tumor specimens and
regional lymph nodes was confirmed with hematoxylin-
eosin staining and diagnosed as pancreatic cancer
independently by two pathologists. The 7th Union
International Cancer Control (UICC) TNM staging system
was applied after surgery combined with imaging manifes-
tations [20]. Overall survival (OS) was defined as the inter-
val between the date of definite diagnosis and date of
death or the last follow up. The clinical and pathological
features of the 72 primary pancreatic carcinoma patients
are summarized in Table 1.
Immunohistochemistry (IHC)
IHC was performed on 72 primary and 20 metastatic
pancreatic cancer tissues according to standard methods
as described previously [21]. Briefly, the tissue sections
Table 1 Clinical and pathological characteristics of 72
patients with primary pancreatic cancer




























Low expression 34 (47.2)
High expression 38 (52.8) Table 2 Clinical and pathological characteristics of 20
patients with metastatic pancreatic cancer












Low expression 15 (75.0)
High expression 5 (25.0)
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rehydrated in a series of graded alcohols. To quench en-
dogenous peroxidase activity, the sections were then
treated with 3% hydrogen peroxide in methanol for
20 min at 37°C, and the antigens were retrieved in
10 mM citrate buffer (pH 6.0) using a microwave oven.
The sections were then incubated overnight at 4°C with
a 1:50 dilution of rabbit anti-PAK1 (Cell Signaling,
#2602) diluted in Dako Antibody Diluent (Dako, ZLI-
9030). The next day, tissue sections were treated with
anti-rabbit secondary antibody for 30 min, developed
with diaminobenzidine tetrahydrochloride (DAB) and
counterstained with hematoxylin. The intensity of stain-
ing and the percentage of the stained cells were esti-
mated by two investigators who were blinded to the
patients’ data. The samples were scored according tothe percentage of positive tumor cells as follows: ≤5% =
0; >5% to ≤25% = 1; >25% to ≤50% = 2; >50% to ≤75% = 3;
and >75% = 4. Another score was given according to the
intensity of staining as follows: negative = 0; weak = 1;
moderate = 2; or strong = 3. The final quantitation of each
staining was obtained by multiplying the two scores. PAK1
expression was classified as low expression for the final
scores <4 and high expression for scores ≥4.
Statistical analysis
The χ2 test was used for statistical analysis of interdepend-
ence between PAK1 expression and clinical factors. Sur-
vival curves were constructed using the Kaplan-Meier
method and analyzed using the log-rank test. Survival data
were evaluated using univariate and multivariate Cox re-
gression analyses. The hazard ratio and its 95% confidence
interval were recorded for each clinicopathological param-
eter. All statistical analyses were performed using SPSS
software (version 16.0; Chicago, IL). P values <0.05 were
considered statistically significant.
Results
PAK1 expression is higher in primary pancreatic cancer
tissues than in metastatic tissues
The clinical and pathological characteristics of patients
with primary and metastatic pancreatic cancer are shown
in Table 1 and Table 2. PAK1 protein expression was sig-
nificantly higher in the 72 human primary pancreatic can-
cer tissues compared to the 20 liver metastatic tissues
(Figure 1) as determined by IHC. Positive staining was ob-
served in the cytoplasm of the human primary and meta-
static pancreatic cancer samples. Samples were analyzed as
described in Methods, and staining scores less than
four were defined as low PAK1 expression. The rate of
Figure 1 Immunohistochemistry of PAK1 expression in human
primary pancreatic cancer tissues and metastatic liver samples.
Original magnifications: ×100 (left column) and × 200 (right column).
(a) Representative images showing very weak cytoplasmic PAK1
staining (brown) in poorly differentiated metastatic pancreatic
cancer tissues. (b–d) Representative images showing an obvious
trend of increasing cytoplasmic PAK1 staining (brown) in poorly,
moderately and well differentiated primary pancreatic cancer
tissues, respectively.
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mary pancreatic cancer samples (38/72, 52.8%) than in
metastatic pancreatic cancer samples (5/20, 25.0%) (P =
0.028).
High PAK1 expression is associated with younger onset
age and well differentiated tumor
The 72 primary pancreatic cancer specimens included 6
cases of clinical stage I (8.4%), 38 cases of stage II (52.8%),
14 cases of stage III (19.4%) and 14 cases of stage IV
(19.4%) pancreatic cancer. Low PAK1 expression was de-
tected in 34/72 (47.2%) pancreatic carcinomas, while high
PAK1 expression was detected in 38/72 cases (52.8%). No
significant correlation between PAK1 protein expression
and clinical characteristics, such as gender or clinical
stage, was found. However, PAK1 was associated with age
(P = 0.038) and pathologic differentiation (P = 0.007). Therate of high PAK1 expression was significantly higher in
young patients (≤60 years old) than in senior patients
(>60 years old) (63.4% vs 38.7%, respectively; P = 0.038). In
addition, poor pathological differentiation was associated
with low PAK1 expression. In contrast, high PAK1 expres-
sion was detected in well differentiated samples (Figure 1).
The rates of high PAK1 expression in poorly compared to
moderately to well differentiated samples were 39.0% (16/
41) and 71.0% (22/31), respectively. Data regarding PAK1
expression in relation to clinical and pathological parame-
ters are summarized in Table 3.
PAK1 expression may be a prognostic factor for
pancreatic cancer
Survival analysis showed that OS was significantly differ-
ent among 72 patients according to PAK1 expression sta-
tus (P < 0.005) (Figure 2) by using the Kaplan-Meier
analysis and log-rank test. Patients with high PAK1 ex-
pression had a significantly longer OS than those with low
PAK1 expression (median OS, 23.3 vs. 12.0 months, re-
spectively). In univariate analysis for primary pancreatic
cancer patients, PAK1 expression status (P = 0.004), differ-
entiation (P = 0.017) and clinical stage (P = 0.001) were
prognostic factors. In multivariate analysis by Cox regres-
sion, PAK1 expression (P = 0.003) and clinical stages (P =
0.002) were two prognostic factors (Table 4). Together
these findings indicated that PAK1 may be a novel prog-
nostic factor for survival in pancreatic cancer patients.
Discussion
The expression levels of PAKs are elevated in many ma-
lignancies and play an important role in the regulation
of cell morphogenesis, motility, mitosis and angiogenesis
[16,22-25]. Our IHC analysis of 72 primary pancreatic
cancer samples and 20 liver metastatic samples revealed
that PAK1 expression was lower in liver metastatic sites
of pancreatic cancer compared to primary pancreatic
cancer tissues. The rate of high PAK1 expression in pri-
mary pancreatic cancer samples was twice as high as the
rate in metastatic pancreatic cancer samples (52.8% vs
25.0%, respectively). Our results presented here are dif-
ferent from previous studies in other tumors. Kamai
et al. found that PAK1 overexpression is associated with
lymphovascular invasion and lymph node metastasis of
upper urinary tract cancer [26]. Ching et al. found that
overexpression of PAK1 in human hepatocellular carcin-
omas was associated with more aggressive tumor behav-
ior and more advanced tumor stages [24]. The authors
also found that PAK1-induced cancer metastasis may in-
volve activation of c-Jun NH2-terminal kinase (JNK) and
phosphorylation of paxillin. Another study demonstrated
that PAK1 induced colorectal cancer metastasis via extra-
cellular signal-regulated kinase (ERK)-dependent phos-
phorylation of focal adhesion kinase (FAK) [27].
Table 3 Correlation analysis between PAK1 expression and clinicopathological characteristics in 72 patients with
primary pancreatic cancer
Characteristics PAK1 P-value
Low/none No. cases (%) High No. cases (%)
Gender Male 18 (45.0% ) 22(55.0%) 0.673
Female 16(50.0%) 16(50.0%)
Age (years) ≤ 60 15(36.6%) 26(63.4%) 0.038
> 60 19(61.3%) 12(38.7%)
Pathologic differentiation Poor 25(61.0%) 16(39.0%) 0.007
Moderate/Well 9(29.0%) 22(71%)
Clinical stage I-III 29(50.0% ) 29(50.0%) 0.706
IV 5(35.7%) 9(64.3%)
T classification T1 + T2 4(33.3%) 8(66.7%) 0.291
T3 + T4 30(50.0%) 30(50.0%)
N classification No 20 (44.4%) 25(55.6%) 0.542
Yes 14 (51.9%) 13 (48.1%)
M classification M0 29 (50.0%) 29 (50.0%) 0.337
M1 5 (35.7%) 9 (64.3%)
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0.05) and pathologic differentiation (P < 0.05). Immunohis-
tochemical results showed that poor differentiation was
correlated with lower PAK1 expression and well differenti-
ation was correlated with higher PAK1 expression. Several
recent studies showed that overexpression of PAK1 is asso-
ciated with poor differentiation in gastric cancer, colorectal
cancer and breast cancer [16,27,28]. In addition, the sub-
cellular localization of PAK1 staining is related to clinico-
pathologic tumor parameters in breast cancer. Cytoplasmic
PAK1 staining was strongly correlated with histological
grade and the level of tumor cell proliferation, while posi-
tive nuclear PAK1 staining was correlated with tumor cellFigure 2 Kaplan-Meier survival curves for primary pancreatic cancer p
Low PAK1 expression is indicated by a dotted line, and high PAK1 expressi
(clinical stages I–IV) with low/high PAK1 expression. (b) The overall survival
(c) The overall survival of patients (clinical stages IV) with low/high PAK1 exproliferation [28]. In a pancreatic cancer study, Makisumi
et al. immunized Balb/c mice with human pancreatic
adenocarcinoma xenografts [19] and demonstrated a
stronger positive PAK1 immunostaining in moderately
and well differentiated pancreatic cancer compared to
poorly differentiated pancreatic cancer. Furthermore,
acinar cells of the normal fetal pancreas showed strong
positive PAK1 staining in the cytoplasm, while the
normal adult pancreas consisting of only islets of
Langerhans showed weak staining of PAK1. This sug-
gests that PAK1 may recognize a certain category of
oncofetal antigens that are differentially expressed on
pancreatic carcinomas.atients with low PAK1 expression versus high PAK1 expression.
on is indicated by a solid line. (a) The overall survival of patients
of patients (clinical stages I–III) with low/high PAK1 expression.
pression.
Table 4 Univariate and multivariate Cox-regression
analysis of various prognostic parameters in patients
with primary pancreatic cancer
Variables Univariate analysis Multivariate analysis
No. P value Hazard ratio 95% CI P value
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sion of PAK1 was associated with poor prognosis in colo-
rectal cancer, ovarian cancer, and breast cancer [18,28-30].
A recent study revealed that PAK1 expression increased
with the progression of colorectal cancer. The expression
of PAK1 in colon cancer cells promoted transformation
through facilitating the ERK/MAPK (mitogen-activated
protein kinases) pathway and enhanced cell migration and
survival by stimulating AKT [31]. In other studies, PAK1
genomic amplification found at 11q13 was prevalent in
luminal breast cancer and breast cancer cells. After inhibit-
ing PAK1, cancer cells rapidly underwent apoptosis. Fur-
thermore, strong nuclear and cytoplasmic PAK1 expression
was also prevalent in squamous non-small cell lung carcin-
omas, and selective PAK1 inhibition was associated with
delayed cell cycle progression in vitro and in vivo [32,33].
These studies implicate an important role for PAK1 in the
regulation of cell motility and tumor cell invasiveness.
Two recent studies examined PAK1 expression in pan-
creatic cancer. Jagadeeshan et al. reported that PAK1
levels are significantly upregulated in pancreatic ductal
adenocarcinoma samples compared with adjacent nor-
mal samples [34]. The authors also found that PAK1
knockdown clones failed to form tumors in nude mice.
However, they did not compare PAK1 expression levels
among pancreatic cancer tissues. Yeo et al. showed that
the natural product glaucarubinone reduced pancreaticcancer cell growth, at least in part via inhibition of path-
ways involving PAK1 and PAK4 [35]. The current study
is the first to investigate the expression levels and prog-
nostic value of PAK1 in human primary and metastatic
pancreatic carcinoma.
A striking finding from our study was the correlation of
high PAK1 expression with a better survival outcome in
primary pancreatic cancer patients. The multivariate Cox
model analysis identified PAK1 as a possible prognostic
factor in pancreatic cancer patients. Additionally, PAK1
expression was lower in liver metastatic sites of pancreatic
cancer compared to primary pancreatic cancer tissues.
Jagadeeshan et al. found that PAK1 plays an important
role in cancer formation. Our results indicate that PAK1
may play a critical role in the initial phase of carcinogen-
esis rather than tumor development or metastasis in pan-
creatic carcinoma. This may also indicate that PAK1 does
not promote tumor metastasis in pancreatic cancer pa-
tients. Nevertheless, the exact molecular mechanism by
which PAK1 is involved in pancreatic cancer development
and progression still remains unclear. Thus, further inves-
tigations of PAK1 expression in pancreatic cancer will be
needed to elucidate the precise mechanism for its exact
regulatory pathway in vitro and in vivo.
Conclusion
Our study was the first to demonstrate high PAK1 expres-
sion in primary pancreatic cancer tissues compared to
liver metastatic tissues of pancreatic cancer. In addition,
reduced expression of PAK1 correlated with poor histo-
logical differentiation in pancreatic cancer and closely cor-
related with poorer OS.
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